Organization · Venture Capital
o2h Ventures
o2h Ventures is a UK-based investment firm specializing in early-stage biotechnology companies, focusing on therapeutics and AI-driven healthcare innovations. The firm operates from the Mill SciTech Park in Cambridge, providing incubation and support for life science startups.
Overview
What o2h Ventures does
What o2h Ventures is
o2h Ventures is a UK-based investment firm specializing in early-stage biotechnology companies, focusing on therapeutics and AI-driven healthcare innovations. The firm operates from the Mill SciTech Park in Cambridge, providing incubation and support for life science startups.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2018
- Approximate age
- About 8 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find o2h Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
o2h Ventures as a funder
Investment thesis
o2h Ventures focuses on seeding early-stage biotech therapeutics and AI opportunities, leveraging strong relationships within the biotech community to access innovative ideas early.
Focus narrative
o2h Ventures invests primarily in early-stage companies within the biotechnology sector, particularly those focused on novel drug discovery and enabling services, tools, and AI technologies. The firm aims to support startups that are developing groundbreaking solutions in human health, leveraging its unique position within the Cambridge biotech ecosystem.
Value beyond capital
o2h Ventures provides significant value to its portfolio companies through capital investment, scientific support, strategic mentorship, and access to co-working lab and office space. The firm leverages its deep connections within the biotech community to facilitate collaborations and operational assistance, ensuring that startups have the resources they need to succeed.
Terms and economics
- Typical check
- $25,000–$100,000
Focus and fit
- Stages
- Pre-seed · Seed
- Regions
- United KingdomEurope
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
Portfolio context
CamGene Therapeutics: Developing RNA-based therapeutics for hearing loss, linked to the University of Cambridge. Cybin: A neuropsychiatry company focused on innovative mental health solutions. Enedra Therapeutics: Specializes in personalized medicines for heterogeneous cancers. Sansanima Ltd: University of Sheffield spinout creating in vitro assay technologies to replace animal testing. Atelerix Ltd: Develops hypothermic gel-based technology for preserving live cells and tissues. Exonate: Focused on eye-drop treatments for retinal diseases, partnered with Johnson & Johnson.
Common questions
What to know about o2h Ventures
Upseed classifies o2h Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.